Researchers in Los Angeles have developed a nanomed that can take on two crucial roles--diagnosing brain tumors and delivering the drugs that can take them down.
Celldex has added another round of positive data demonstrating that its brain cancer vaccine rindopepimut--more formally called Rintega and less formally "rindo"--provided a clear though relatively modest average survival benefit for recurrent glioblastoma patients in a Phase II study. And with the initial data set from Phase III looming later in the year, the biotech is carefully moving forward with its ongoing dialogue with regulators to gauge just how receptive they may be to speeding up an approval.
Researchers at Northwestern University have put together a nanostructure capable of shuttling a new RNA molecule across the blood-brain barrier to reach tumor cells in mice with glioblastoma multiforme, a particularly aggressive form of brain cancer.
Zeroing in on an enzyme that is over-expressed in brain tumor cells, two investigators at Houston Methodist say they have developed a new treatment for gliomas that has cleared its preclinical testing and should be ready for human testing within the next one to two years.
Investigators say that they've identified a pathway that can be used to target brain tumor stem cells, adding to potential therapeutic strategies for the aggressive disease glioblastoma.
Canada's Monteris Medical announced a $30 million equity financing for its NeuroBlate robotic neurosurgical system to ablate, or destroy using heat, brain lesions like primary and metastatic tumors.
After putting up evidence to show that the liver toxicity triggered by its lead drug can be reversed, the FDA has lifted the full hold placed on its lead--and only--cancer drug. And investors responded enthusiastically to the biotech's return to the clinic, boosting shares by 35% in premarket trading.
Researchers in California believe they've zeroed in on biomarkers--microRNAs--that will help determine who will respond best to the treatment and help boost its success rate.
Patients with a lethal form of brain cancer lived nearly twice as long as expected after receiving Agenus' ($AGEN) Prophage vaccine in a Phase II study, according to the company.
The cancer vaccine field has seen its share of late-stage disappointments and outright flops, but a number of hopefuls are lining up to present new research backing their experimental shots at this year's upcoming American Society of Clinical Oncology Annual Meeting in Chicago.